Now showing items 21-40 of 84

      Covid-19 vaccine trial protocols released [1]
      Covid-19: Do many people have pre-existing immunity? [1]
      Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available? [1]
      Data too important to share: do those who control the data control the message? [1]
      Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing [1]
      Determining the infectious potential of individuals with positive RT-PCR SARS-CoV-2 tests [1]
      Does oseltamivir really reduce complications of influenza? [1]
      EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood [1]
      The elusive definition of pandemic influenza [1]
      EMA recommendation on hydroxyethyl starch solutions obscured controversy [1]
      EMA scales back transparency initiatives because of workload [1]
      Ensuring safe and effective drugs: who can do what it takes? [1]
      The evidence base for new drugs [1]
      FDA drug summaries: a simplification too far? [1]
      FDA to begin releasing clinical study reports in pilot programme [1]
      FDA unease about faster drug approval [1]
      From promises to policies: is big pharma delivering on transparency? [1]
      The imperative to share clinical study reports: recommendations from the Tamiflu experience [1]
      Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial [1]
      “Independent” reanalysis of landmark starch solutions trial was published by original authors [1]